A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1059-1069

  Gu, Wen Zhen ^a   Joseph, Ingrid ^a   Wang, Yi Chun ^a   Frost, David ^a   Sullivan, Gerard M ^a   Wang, Le ^a   Lin, Nan Horng ^a   Cohen, Jerry ^a   Stoll, Vincent S ^a   Jakob, Clarissa G ^a   Muchmore, Steven W ^a   Harlan, John E ^a   Holzman, Tom ^a   Walten, Karl A ^a   Ladror, Uri S ^a   Anderson, Mark G ^a   Kroeger, Paul ^a   Rodriguez, Luis E ^a   Jarvis, Kenneth P ^a   Ferguson, Debra ^a   Marsh, Kennan ^a   Ng, Shichung ^a   Rosenberg, Saul H ^a   Sham, Hing L ^a   Zhang, Haiying ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

Angiogenesis; Animal model; Crystal structure; Farnesyltransferase inhibitor; Ras

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; A 367074; ABT 100; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; GERANYLGERANYLTRANSFERASE; GERANYLTRANSFERASE; LONAFARNIB; MESSENGER RNA; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAP PROTEIN; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL STRAIN 3T3; COLON CARCINOMA; COLONY FORMATION; CONTROLLED STUDY; CORNEA VASCULARIZATION; CRYSTAL STRUCTURE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE RAS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TUMOR XENOGRAFT; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASMS; RAS PROTEINS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27644561477     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00004     Document Type: Article

References (26)

1. Gibbs J, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997; 37:143-166.
2. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, et al. Sequence dependence of protein isoprenylation. J Biol Chem 1991; 266:14603-14610.
3. Prendergast GC, Oliff A. Characterization of prenyl groups attached to K-Ras in DLD-1 human colon carcinoma cells treated with the FPT inhibitor SCH 44342. Proc Am Ass Cancer Res 1996; 37:503.
4. Cox AD. Farnesyltransferase inhibitors: potential role in the treatment of cancer. Drugs 2001; 61:723-732.
5. Prendergast GC, Oliff A. Farnesynlation inhibitors: antineoplastic mechanism and clinical prospects. Semin Cancer Biol 2000; 10:443-452.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
7. Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333:267-283.
8. Widemann BC, Fox E, Goodspeed W, Goodwin A, Jayaprakash N, Pitney A, et al. Phase I trial of the farnesyltransferase inhibitor (FTI) R115777 in children with refractory leukemias. Proc Am Soc Clin Oncol 2003; 22:809.
9. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer, 2002; 38:2272-2278.
10. Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Invest Drugs, 2003; 12:943-954.
11. Zhu K, Hamilton A, Sebti S. Farneysltransferase inhibitors as anticancer agent: current status. Curr Opin Invest Drug 2003; 21:1428-1435.
12. Strickland C, Windsor WT, Syto R, Wang L, Bond R, Wu Z, et al. Biochemistry 1998; 37:16601.
13. Otwinowski Z, Minor W. Methods Enzymol 1997; 276:307-326.
14. Brunger AT, Adams PD, Clore GM, Delano WL, Gros P, Grasse-Kunstleve RW, et al. Biol Crystallogr 1998; 54:905.
15. Badger J, Berard D, Kumar RA, Szalma S, Yip P, Griesinger C, et al. CNX software manual. San Diego, California: Molecular Simulations; 1999.
16. Tahir SK, Gu WZ, Zhang HC, Leal J, Lee JY, Kovar P, et al. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur J Cancer 2000; 36:1161-1170.
17. http://dtpsearch.ncifcrf.gov/DATA/MOLECULAR_TARGETS/TABLES/RHODVAL.HTML
18. Wang E, Casciano CN, Clement RP, Johnson WW. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001; 61:7525-7529.
19. Long SB, Casey PJ, Beese LS. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002; 419:645.
20. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995; 270:25915-25919.
21. Okada F, Rak JW, Croix BS, Lieubeau B, Koya M, Roncari L, et al. mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998; 95:3609-3614.
22. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996; 56:5391-5396.
23. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1:1024-1028.
24. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55:4575-4580.
25. Gu WZ, Tahir SK, Wang YC, Zhang HC, Cherian SP, O'Connor S, et al. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer 1999; 35:1394-1401.
26. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94:8761-8766.